Advanced Biomed Inc.(ADVB)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
ADVB Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Advanced Biomed Inc. (ADVB), a Healthcare sector company. ADVB is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q3 2026), Advanced Biomed Inc. reports net income of $-488.9K, free cash flow of $-241.0K. Top institutional holders of ADVB by reported 13-F value include XTX Topco Ltd, UBS Group AG, Virtu Financial, based on the most recent SEC filings. ADVB trades on the Nasdaq exchange and files with the SEC under CIK 1941029. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ADVB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Advanced Biomed Inc. directly from SEC EDGAR.
Net Income
Q3 2026
$-488.9K
Free Cash Flow
Q3 2026
$-241.0K
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Net Income
-17.1% YoYEPS (Diluted)
-14.3% YoYTotal Assets
+207.6% YoYOp. Cash Flow
-173.9% YoY| Metric | FY 2025 | FY 2024 |
|---|---|---|
| Net Income | $-3.3M -17.1% | $-2.8M |
| EPS (Diluted) | $-0.16 -14.3% | $-0.14 |
| Total Assets | $13.7M +207.6% | $4.5M |
| Operating Cash Flow | $-5.8M -173.9% | $-2.1M |
AI Insight: ADVB Financial Trends
Net income swung to $7M profit in Q4 2025 after three quarters of losses, but cash burn persists and equity funding masks operational challenges.
• Net income recovered to $7M in Q4 2025 from $-1M in Q1–Q2 2025, marking first significant profitability in the period.
• Equity doubled from $1M (Q4 2024) to $9M (Q4 2025–Q1 2026), signaling capital injection to offset losses.
⚠ Operating cash flow negative across all six quarters, ranging $-0M to $-3M; no cash generation despite Q4 2025 profit.
⚠ Net income returned to break-even/loss in Q1 2026 after Q4 2025 spike; sustainability of profitability unclear.
AI Insight: ADVB Ratio Trends
ADVB swung from severe losses (ROE −134% in Q1 2025) to near-breakeven (ROE −21.2% in Q1 2026), signaling operational stabilization but not yet profitability.
• ROE improved 112.8pp from Q1 2025 (−134.0%) to Q1 2026 (−21.2%); ROA similarly recovered from −66.8% to −18.4%.
• TTM ROE and ROA now strongly positive at 57.3% and 49.6%, respectively, indicating full-year 2025–early 2026 profitability turnaround.
⚠ Q1 2026 still shows negative ROE/ROA/ROIC (−21.2%, −18.4%, −21.2%), suggesting the quarter itself remains unprofitable despite TTM recovery.
⚠ Large gap between TTM returns (57.3% ROE) and latest quarter (−21.2% ROE) points to substantial prior-quarter earnings; watch for sustainability.
Get alerted when ADVB's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Advanced Biomed Inc. including:
Top Institutional Holders of ADVB
XTX Topco Ltd
$8.0K27,264 shUBS Group AG
$1.3K4,324 shVirtu Financial LLC
$4.0012,561 sh
| Fund | Value | Shares |
|---|---|---|
| XTX Topco Ltd | $8.0K | 27,264 |
| UBS Group AG | $1.3K | 4,324 |
| Virtu Financial LLC | $4.00 | 12,561 |
More Healthcare Companies
View all Healthcare →Put ADVB on your watchlist
Track score changes the day Advanced Biomed Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ADVB a good stock to buy?
13F Pro's AI-powered analysis of Advanced Biomed Inc. (ADVB) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ADVB are available on the ADVB stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own ADVB?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ADVB. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Advanced Biomed Inc.'s investment landscape.